EU regulators see info from rivals, customers in Catalent sale to Novo Holdings - Reuters
European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.
EU regulators see info from rivals, customers in Catalent's sale to Novo Holdings
European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 billion deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
FierceBiotech3d
Novo Holdings, OrbiMed, Jeito lead $181M fundraise for ADC biotech
Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...
Novo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK ...